ClinicalTrials.gg
CompletedNCT00061594Updated Mar 19, 2014

A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration

A Phase 3 interventional study of rhuFab V2 (ranibizumab) in Macular Degeneration, sponsored by Genentech, Inc.. Completed at 82 sites in 6 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2014-03-19.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
426
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Enrollment
18th of 124
426 · median 64
Started
2003
with 2 others
Phase 3
31 of 125
2 open now
Registered
3rd of 125
by date
Lead sponsor
11 of 125
Genentech, Inc.

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 18th largest by enrollment of the 124 interventional ones that give a count, is one of 3 that started in 2003, is one of 31 in phase 3, and was the 3rd registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

This is a phase III, multicenter, randomized, double-masked, active treatment-controlled study of intravitreally administered ranibizumab compared with verteporfin (Visudyne) photodynamic therapy (PDT) in treating subfoveal neovascular mascular degeneration.

03

Conditions studied

  • Macular Degeneration

Keywords

  • Neovascular age-related macular degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Age >=50 years
  • Eligibility for treatment with PDT using verteporfin in the study eye according to the Visudyne product labeling
  • Future treatment with PDT using verteporfin anticipated or expected in the study eye
  • Primary or recurrent subfoveal choroidal neovascularization (CNV) lesions secondary to age-related macular degeneration (AMD) in the study eye
  • A classic CNV component (well-demarcated hyperfluorescence boundaries in the early phase of the fluorescein angiogram) that is >=50% of the total lesion size
  • Total lesion size of less than or equal to 5400 um in greatest linear dimension (GLD)
  • Best corrected visual acuity, using Early Treatment of Diabetic Retinopathy Study (ETDRS) charts, of 20/40 to 20/320 (Snellen equivalent) in the study eye

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with verteporfin, external-beam radiation therapy, or transpupillary thermotherapy (TTT) in the study eye
  • Treatment with verteporfin in the non-study eye less than 7 days preceding Day 0
  • Previous participation in a clinical trial (for either eye) involving anti angiogenic drugs (pegaptanib, ranibizumab, anecortave acetate, protein kinase C inhibitors, etc.)
  • Previous intravitreal drug delivery (e.g., intravitreal injection or device implantation) in the study eye
  • Previous subfoveal focal laser photocoagulation in the study eye
  • Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1 month preceding Day 0
  • History of vitrectomy surgery in the study eye
  • History of submacular surgery or other surgical intervention for AMD in the study eye
  • Previous participation in any studies of drugs within 1 month preceding Day 0 (excluding vitamins and minerals)
  • Subretinal hemorrhage in the study eye that involves the center of the fovea, if the size of the hemorrhage is either >=50% of the total lesion area or >=1 disc area (DA) in size
  • Subfoveal fibrosis or atrophy in the study eye
  • CNV in either eye due to other causes, such as ocular histoplasmosis, trauma, or pathologic myopia
  • Retinal pigment epithelial tear involving the macula in the study eye
  • Any concurrent intraocular condition in the study eye (e.g., cataract or diabetic retinopathy) that, in the opinion of the Investigator could either: (1) Require medical or surgical intervention during the 24-month study period to prevent or treat visual loss that might result from that condition, or (2) If allowed to progress untreated, could likely contribute to loss of at least 2 Snellen equivalent lines of best corrected visual acuity over the 24-month study period
  • Active intraocular inflammation (grade trace or above) in the study eye
  • Current vitreous hemorrhage in the study eye
  • History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study eye
  • History of idiopathic or -associated uveitis in either eye
  • Infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
  • Aphakia or absence of the posterior capsule in the study eye
  • Spherical equivalent of the refractive error in the study eye demonstrating more than -8 diopters of myopia
  • Intraocular surgery (including cataract surgery) in the study eye within 2 months preceding Day 0
  • Uncontrolled glaucoma in the study eye (defined as intraocular pressure >=30 mmHg despite treatment with anti-glaucoma medication)
  • History of glaucoma filtering surgery in the study eye
  • History of corneal transplant in the study eye
  • Premenopausal women not using adequate
  • History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect interpretation of the results of the study or render the subject at high risk for treatment complications
  • Current treatment for active systemic infection
  • History of allergy to fluorescein, not amenable to treatment
  • Inability to obtain fundus photographs or fluorescein angiograms of sufficient quality to be analyzed and graded by the central reading center
  • Inability to comply with study or follow up procedures
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Masking
Double
Enrollment
426 participants

Interventions

06

Study locations

82 sites
  • Retina Centers, P.C.
    Tucson, Arizona 85704, United States
  • University of Arizona
    Tucson, Arizona 85711, United States
  • Retina-Vitreous Associates Medical Group
    Beverly Hills, California 90211, United States
  • UC Irvine
    Irvine, California 92697, United States
  • Doheny Eye Institute
    Los Angeles, California 90033, United States
  • California Vitreoretinal Research Center
    Menlo Park, California 94025, United States
  • No. California Retina-Vitreous Associates
    Mountain View, California 94040, United States
  • UCSF School of Medicine
    San Francisco, California 94143, United States
  • Danbury Eye Physicians & Surgeons
    Danbury, Connecticut 06810, United States
  • New England Retina Associates
    Hamden, Connecticut 06518, United States
  • Florida Retina Institute
    Daytona Beach, Florida 32114, United States
  • Retina Vitreous Consultants
    Ft. Lauderdale, Florida 33334, United States
  • Retina Consultants of Southwest Florida
    Ft. Myers, Florida 33901, United States
  • Retina Health Center
    Ft. Myers, Florida 33901, United States
  • Retina Associates of South Florida
    Margate, Florida 33063, United States
  • Bascom Palmer Eye Institute
    Miami, Florida 33136, United States
  • Central Florida Retina
    Orlando, Florida 32806, United States
  • Retina Care Specialists
    Palm Beach Gardens, Florida 33410, United States
  • Bascom Palmer Eye Institute
    Palm Beach Gardens, Florida 33418, United States
  • Ophthalmic Consultants
    Sarasota, Florida 34239, United States
  • Southern Vitreoretinal Associates PA
    Tallahassee, Florida 32308, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Medical College of Georgia
    Augusta, Georgia 30912, United States
  • Thomas A. Ciulla, MD, PC
    Indianapolis, Indiana 46280, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Retina Associates PC
    Annapolis, Maryland 21401, United States
  • New England Eye Center
    Boston, Massachusetts 02111, United States
  • Center for Eye Research
    Boston, Massachusetts 02114, United States
  • New England Retina Consultants
    West Springfield, Massachusetts 01089, United States
  • University of Michigan
    Ann Arbor, Michigan 48105, United States
  • Associated Retinal Consultants
    Grand Rapids, Michigan 49546, United States
  • Associated Retinal Consultants, P.C.
    Royal Oak, Michigan 48073, United States
  • Retina Consultants of Michigan
    Southfield, Michigan 48034, United States
  • Retina Associates of St. Louis
    Florissant, Missouri 63031, United States
  • St. Louis University Eye Institute
    St. Louis, Missouri 63104, United States
  • Delaware Valley Retina Associates
    Lawrenceville, New Jersey 08648, United States
  • Lions Eye Institute
    Albany, New York 12208, United States
  • Ophthalmic Consultants of Long Island
    Rockville Centre, New York 11570, United States
  • Western Carolina Retinal Associates, PA
    Asheville, North Carolina 28803, United States
  • Southeast Clinical Research
    Charlotte, North Carolina 28210, United States
  • Duke Univ Medical Center/Duke Eye Center
    Durham, North Carolina 22710, United States
  • Retina Associates of Cleveland
    Beachwood, Ohio 44122, United States
  • Flavio Company
    Cincinnati, Ohio 45242, United States
  • Cleveland Clinic Foundation/Cole Eye Institute
    Cleveland, Ohio 44195, United States
  • Midwest Retina
    Columbus, Ohio 43215, United States
  • Retina Vitreous Associates
    Toledo, Ohio 43608, United States
  • Retinal Associates of Oklahoma
    Oklahoma City, Oklahoma 73120, United States
  • Retina & Vitreous Center of So. Oregon
    Ashland, Oregon 97520, United States
  • Pennsylvania Retina Specialists
    Camp Hill, Pennsylvania 17011, United States
  • Wills Eye Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • Retina Consultants of Charleston
    Charleston, South Carolina 29414, United States
  • Palmetto Retina Center
    Columbia, South Carolina 29204, United States
  • BH Regional Eye Institute
    Rapid City, South Dakota 57701, United States
  • Southeastern Retina Associates, P.C.
    Knoxville, Tennessee 37909, United States
  • Retina Vitreous Associates
    Nashville, Tennessee 37203, United States
  • Austin Retina Associates
    Austin, Texas 78705, United States
  • Brian Berger, MD P.A.
    Austin, Texas 78705, United States
  • Retina Specialists
    Desoto, Texas 75115, United States
  • UTMB
    Galveston, Texas 77555, United States
  • Vitreoretinal Consultants
    Houston, Texas 77030, United States
  • Valley Retina Institute, P.A.
    McAllen, Texas 78503, United States
  • Univ of Texas Health Science Center
    San Antonio, Texas 78229, United States
  • Medical Center Ophthalmology
    San Antonio, Texas 78240, United States
  • Rocky Mountain Retina Consultants
    Salt Lake City, Utah 84107, United States
  • John Moran Eye Center/Univ of Utah
    Salt Lake City, Utah 84132, United States
  • Retina Group of Washington
    Fairfax, Virginia 22031, United States
  • Vitreoretinal Associates
    Seattle, Washington 98104, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • University of Melbourne, Department of Ophthalmology
    East Melbourne, VIC-3002, Australia
  • Marsden Eye Research Pty Ltd
    Parramatta, NSW 2150, Australia
  • Save Sight Institute
    Sydney, NSW-2000, Australia
  • Westmead Hospital
    Westmead, NSW-2145, Australia
  • Onci klinika FNKV
    Praha 10, 100 00, Czech Republic
  • Clinique d'Ophtalmologie
    Creteil Cedex, F-94010, France
  • Clinique Monticelli
    Marseille, F-13008, France
  • Hôpital Lariboisière
    Paris Cedex 10, F-75475, France
  • Universitätsklinikum Bonn
    Bonn, D-53105, Germany
  • Universitatskliniken Koln
    Koln, D-50924, Germany
  • Universitätsklinikum Leipzig
    Leipzig, D-04103, Germany
  • Semmelweis University, 1st Ophthalmological Department
    Budapest, H-1083, Hungary
07

References and documents

Publications

  • Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1432-44. doi: 10.1056/NEJMoa062655. PubMed 17021319 ↗
  • Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007 Dec;144(6):850-857. doi: 10.1016/j.ajo.2007.08.012. Epub 2007 Oct 22. PubMed 17949673 ↗
  • Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009 Jan;116(1):57-65.e5. doi: 10.1016/j.ophtha.2008.10.018. PubMed 19118696 ↗
  • Suner IJ, Kokame GT, Yu E, Ward J, Dolan C, Bressler NM. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3629-35. doi: 10.1167/iovs.08-3225. Epub 2009 Feb 28. PubMed 19255158 ↗
  • Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J; Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Research Group. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Arch Ophthalmol. 2009 Jan;127(1):13-21. doi: 10.1001/archophthalmol.2008.562. PubMed 19139332 ↗
  • Thach AB, Yau L, Hoang C, Tuomi L. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials. Ophthalmology. 2014 May;121(5):1059-66. doi: 10.1016/j.ophtha.2013.11.022. Epub 2014 Jan 11. PubMed 24424249 ↗
  • Weinberg DV, Shapiro H, Ehrlich JS. Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology. 2013 Jun;120(6):1278-82. doi: 10.1016/j.ophtha.2012.11.042. Epub 2013 Feb 28. PubMed 23453513 ↗
  • Bressler NM, Chang TS, Varma R, Suner I, Lee P, Dolan CM, Ward J, Ianchulev T, Fine J. Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab. Ophthalmology. 2013 Jan;120(1):160-8. doi: 10.1016/j.ophtha.2012.07.027. Epub 2012 Sep 23. PubMed 23009891 ↗
  • Rosenfeld PJ, Shapiro H, Ehrlich JS, Wong P; MARINA and ANCHOR Study Groups. Cataract surgery in ranibizumab-treated patients with neovascular age-related macular degeneration from the phase 3 ANCHOR and MARINA trials. Am J Ophthalmol. 2011 Nov;152(5):793-8. doi: 10.1016/j.ajo.2011.04.025. Epub 2011 Jul 26. PubMed 21794843 ↗
  • Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B; MARINA and ANCHOR Study Groups. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology. 2011 Mar;118(3):523-30. doi: 10.1016/j.ophtha.2010.07.011. PubMed 20920825 ↗
  • Barbazetto IA, Saroj N, Shapiro H, Wong P, Ho AC, Freund KB. Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. Am J Ophthalmol. 2010 Jun;149(6):939-946.e1. doi: 10.1016/j.ajo.2010.01.007. Epub 2010 Apr 8. PubMed 20378094 ↗
  • Bressler NM, Chang TS, Suner IJ, Fine JT, Dolan CM, Ward J, Ianchulev T; MARINA and ANCHOR Research Groups. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology. 2010 Apr;117(4):747-56.e4. doi: 10.1016/j.ophtha.2009.09.002. Epub 2010 Mar 2. PubMed 20189654 ↗
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2003 and a completion of Sep 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2003
First posted
May 30, 2003
Start
May 2003
CompletionActual
Sep 2006
Last update
Mar 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00061594
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
May 30, 2003
Start date
May 2003
Completion
Sep 2006
Last update
Mar 19, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion